Phaseline

Targets › CTNNB1

CTNNB1 (Catenin beta-1): drug programs, companies and trials

3 programs from 3 companies in 3 trials: 2 Phase 1, 1 Phase 2; Other, Oncology, Hematology; next expected readout Dec 2026.

Key downstream component of the canonical Wnt signaling pathway. In the absence of Wnt, forms a complex with AXIN1, AXIN2, APC, CSNK1A1 and GSK3B that promotes phosphorylation on N-terminal Ser and Thr residues and ubiquitination of CTNNB1 via BTRC and its subsequent degradation by the proteasome. (UniProt, P35222)

Open in Phaseline: the race on CTNNB1, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Kiminori Kimura, MDPri-724
CBP/beta catenin inhibitor
CREBBP, CTNNB1Phase 2Liver CirrhosisNov 2027
Stanford UniversityNiclosamide
Wnt/β-catenin pathway inhibitor
CTNNB1Phase 1Acute Myeloid Leukemia (AML)Dec 2026
CTNNB1 FoundationUrbagen
AAV9-mediated gene replacement therapy encoding human β-catenin protein
CTNNB1Phase 1CTNNB1 Neurodevelopmental SyndromeDec 2032

Conditions

CTNNB1 Neurodevelopmental Syndrome (1) Acute Myeloid Leukemia (AML) (1) Liver Cirrhosis (1)

Modalities

small molecule (2), mixed (1)

Companies

CTNNB1 Foundation (1) Stanford University (1) Kiminori Kimura, MD (1)

Related targets

CREBBP (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.